Overview Dividends

(DGX) Quest Diagnostics - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74834L1008

Diagnostic Testing, Clinical Labs, Pathology Reports, Risk Assessment, Health IT

Health Care Services
Market Cap in USD: 19,674m

IPO / Inception: 1996-12-17
Return 12m vs S&P 500: -0.75%

EPS (Earnings per Share)

EPS CAGR: -51.61%
EPS Trend: -41.9%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 0.69%
Rev. Trend: 30.4%

Last SUE: 3.44
Qual. Beats: 2

Dividends

Dividend Yield	2.28%
Yield on Cost 5y	3.61%
Yield CAGR 5y	6.81%
Payout Consistency	96.5%
Payout Ratio	33.1%

Risk via 5d forecast
Volatility	20.5%
Value at Risk 5%th	29.8%
Relative Tail Risk	-11.50%

Reward TTM
Sharpe Ratio	0.63
Alpha	8.80
CAGR/Max DD	0.29

Character TTM
Hurst Exponent	0.453
Beta	0.242
Beta Downside	0.146

Drawdowns 3y
Max DD	21.18%
Mean DD	7.37%
Median DD	6.68%

Description: DGX Quest Diagnostics December 19, 2025

Quest Diagnostics (NYSE:DGX) is a leading provider of diagnostic testing and related information services in the U.S. and abroad, operating under the Quest brand and several specialty brands (AmeriPath, Dermpath, ExamOne, Quanum). Its offerings span routine to advanced clinical and anatomic pathology tests, risk-assessment solutions for insurers, and health-IT platforms, delivered through a nationwide network of labs, patient service centers, mobile phlebotomists, and call centers.

Key operating metrics (FY 2023) include approximately **$12.6 billion in revenue**, a **~9 % operating margin**, and a **~5 % year-over-year growth in specialty-testing volumes**, driven by rising demand for genetic and oncology panels. The business is sensitive to **Medicare/Medicaid reimbursement policies**, **aging demographics**, and the broader **shift toward value-based care**, which fuels demand for integrated diagnostics and population-health analytics.

For a deeper quantitative assessment of DGX’s valuation and risk profile, you may find ValueRay’s analyst tools helpful for further research.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (969.0m TTM) > 0 and > 6% of Revenue (6% = 651.0m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 2.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 2.52% (prev 5.57%; Δ -3.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 1.89b > Net Income 969.0m (YES >=105%, WARN >=100%)

Net Debt (5.95b) to EBITDA (2.14b) ratio: 2.78 <= 3.0 (WARN <= 3.5)

Current Ratio 1.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (113.0m) change vs 12m ago 0.0% (target <= -2.0% for YES)

Gross Margin 33.30% (prev 32.77%; Δ 0.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 67.20% (prev 59.27%; Δ 7.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.60 (EBITDA TTM 2.14b / Interest Expense TTM 282.0m) >= 6 (WARN >= 3)

Altman Z'' 3.91

(A) 0.02 = (Total Current Assets 2.41b - Total Current Liabilities 2.13b) / Total Assets 16.20b

(B) 0.61 = Retained Earnings (Balance) 9.84b / Total Assets 16.20b

(D) 1.11 = Book Value of Equity 9.80b / Total Liabilities 8.82b

Total Rating: 3.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 65.91

1. Piotroski 8.0pt

2. FCF Yield 5.44%

3. FCF Margin 12.84%

4. Debt/Equity 0.88

5. Debt/Ebitda 2.78

6. ROIC - WACC (= 3.98)%

7. RoE 13.75%

8. Rev. Trend 30.38%

9. EPS Trend -41.92%

What is the price of DGX shares?

As of January 02, 2026, the stock is trading at USD 173.53 with a total of 645,305 shares traded.
Over the past week, the price has changed by -1.37%, over one month by -5.57%, over three months by -4.27% and over the past year by +17.12%.

Is DGX a buy, sell or hold?

Quest Diagnostics has received a consensus analysts rating of 3.89. Therefore, it is recommended to buy DGX.

Strong Buy: 8
Buy: 1
Hold: 10
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the DGX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	198.1	14.1%
Analysts Target Price	198.1	14.1%
ValueRay Target Price	188.8	8.8%

DGX Fundamental Data Overview December 29, 2025

Market Cap USD = 19.67b (19.67b USD * 1.0 USD.USD)
P/E Trailing = 20.6502
P/E Forward = 16.7224
P/S = 1.8133
P/B = 2.6966
P/EG = 1.4173
Beta = 0.616
Revenue TTM = 10.85b USD
EBIT TTM = 1.58b USD
EBITDA TTM = 2.14b USD
Long Term Debt = 5.17b USD (from longTermDebt, last quarter)
Short Term Debt = 677.0m USD (from shortTermDebt, last quarter)
Debt = 6.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.95b USD (from netDebt column, last quarter)
Enterprise Value = 25.62b USD (19.67b + Debt 6.38b - CCE 432.0m)
Interest Coverage Ratio = 5.60 (Ebit TTM 1.58b / Interest Expense TTM 282.0m)
FCF Yield = 5.44% (FCF TTM 1.39b / Enterprise Value 25.62b)
FCF Margin = 12.84% (FCF TTM 1.39b / Revenue TTM 10.85b)
Net Margin = 8.93% (Net Income TTM 969.0m / Revenue TTM 10.85b)
Gross Margin = 33.30% ((Revenue TTM 10.85b - Cost of Revenue TTM 7.24b) / Revenue TTM)
Gross Margin QoQ = 33.70% (prev 34.15%)
Tobins Q-Ratio = 1.58 (Enterprise Value 25.62b / Total Assets 16.20b)
Interest Expense / Debt = 1.08% (Interest Expense 69.0m / Debt 6.38b)
Taxrate = 22.92% (77.0m / 336.0m)
NOPAT = 1.22b (EBIT 1.58b * (1 - 22.92%))
Current Ratio = 1.13 (Total Current Assets 2.41b / Total Current Liabilities 2.13b)
Debt / Equity = 0.88 (Debt 6.38b / totalStockholderEquity, last quarter 7.26b)
Debt / EBITDA = 2.78 (Net Debt 5.95b / EBITDA 2.14b)
Debt / FCF = 4.27 (Net Debt 5.95b / FCF TTM 1.39b)
Total Stockholder Equity = 7.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.98% (Net Income 969.0m / Total Assets 16.20b)
RoE = 13.75% (Net Income TTM 969.0m / Total Stockholder Equity 7.05b)
RoCE = 12.91% (EBIT 1.58b / Capital Employed (Equity 7.05b + L.T.Debt 5.17b))
RoIC = 9.40% (NOPAT 1.22b / Invested Capital 12.94b)
WACC = 5.42% (E(19.67b)/V(26.06b) * Re(6.91%) + D(6.38b)/V(26.06b) * Rd(1.08%) * (1-Tc(0.23)))
Discount Rate = 6.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 78.65% ; FCFE base≈1.25b ; Y1≈1.28b ; Y5≈1.42b
Fair Price DCF = 225.3 (DCF Value 25.07b / Shares Outstanding 111.2m; 5y FCF grow 2.43% → 3.0% )
EPS Correlation: -41.92 | EPS CAGR: -51.61% | SUE: -4.0 | # QB: 0
Revenue Correlation: 30.38 | Revenue CAGR: 0.69% | SUE: 3.44 | # QB: 2
EPS next Quarter (2026-03-31): EPS=2.36 | Chg30d=+0.006 | Revisions Net=+2 | Analysts=11
EPS next Year (2026-12-31): EPS=10.38 | Chg30d=+0.001 | Revisions Net=+2 | Growth EPS=+5.8% | Growth Revenue=+3.6%

Additional Sources for DGX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle